Parasitological failure At 6 months · patients with treating urinary schistosomiasis
Metrifonate 3 x 7.5 mg/kg given two weeks apart probably leads to lower parasitological failure At 6 months compared with placebo (moderate certainty).
1 finding from 1 review
Mean percent egg reduction At 6 months · patients with treating urinary schistosomiasis
1 finding from 1 review
Adverse events · patients with treating urinary schistosomiasis
1 finding from 1 review
Complete suppression of urticaria: intermediate‐term duration of intervention (levocetirizine 5 mg) Global assessment of symptom scores · patients with chronic spontaneous urticaria
1 finding from 1 review
Withdrawals due to adverse events · patients with chronic spontaneous urticaria
Hydroxyzine 25 mg showed no clear difference in adverse events leading to withdrawal: intermediate‐term duration of… compared with placebo (low certainty).
1 finding from 1 review
Complete suppression of urticaria: short‐term duration of intervention (desloratadine 5 mg) Global assessment of symptom scores · patients with chronic spontaneous urticaria
1 finding from 1 review
Complete suppression of urticaria: intermediate‐term duration of intervention (desloratadine 5 mg) Global assessment of symptom scores · patients with chronic spontaneous urticaria
1 finding from 1 review
Adverse effects requiring withdrawal/discontinuation of study medication · patients with chronic spontaneous urticaria
Desloratadine 5 to 20 mg showed no clear difference in adverse effects leading to withdrawal: intermediate‐term duration of… compared with placebo (low certainty).
1 finding from 1 review
Complete suppression of urticaria: short‐term duration of intervention (levocetirizine 5 mg) Global assessment of symptom scores · patients with chronic spontaneous urticaria
1 finding from 1 review
Maintenance of clinical remission · Participants with Crohn's disease in remission
Methotrexate probably leads to higher proportion of patients maintaining clinical remission (high dose… compared with placebo (moderate certainty).
2 findings from 1 review
Antiviral response ‐ 0.5mg/Kg · patients being treated for HIV infection
It is very uncertain whether PRO 140 changes antiviral response: 0.5 mg/kg compared with placebo (very low certainty).
1 finding from 1 review
Individual nadir changes in HIV‐1 RNA level ‐ 5mg/Kg · patients being treated for HIV infection
1 finding from 1 review
Antiviral response ‐ 5mg/Kg · patients being treated for HIV infection
It is very uncertain whether PRO 140 changes antiviral response: 5 mg/kg compared with placebo (very low certainty).
1 finding from 1 review
Individual nadir changes in HIV‐1 RNA level ‐ 0.5mg/Kg · patients being treated for HIV infection
1 finding from 1 review
Intervention not reported
LDL‐Cholesterol rosuvastatin 2.5 mg/day · participantswith normal or abnormal lipid profiles
1 finding from 1 review
Intervention not reported
LDL‐Cholesterol rosuvastatin 5 mg/day · participantswith normal or abnormal lipid profiles
1 finding from 1 review
Serum urate normalisation ≤ 5 mg/dL (≤ 0.3 mmol/L) ‐ not measured · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review
Serum urate normalisation ≤ 5 mg/dL (≤ 0.3 mmol/L) · people with chronic gout
Benzbromarone probably leads to higher serum urate normalisation ≤ 5 mg/dL (≤ 0.3 mmol/L) compared with probenecid (moderate certainty).
1 finding from 1 review
Leaving the study early (2‐10 weeks) vs. standard higher dose (> 7.5‐15 mg/day) · people with the acute phase of schizophrenia
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes leaving the study early (2‐10 weeks) vs. standard higher dose (>… compared with OTHER DOSES (very low certainty).
1 finding from 1 review
Leaving the study early · people with the acute phase of schizophrenia
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes leaving the study early (2‐10 weeks) vs. high dose (> 15‐35 mg/day) compared with OTHER DOSES (very low certainty).
1 finding from 1 review